ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News Equity Offerings

ImmunoGen Announces Proposed Public Offering of Common StockJune 5, 2018 4:03 PM